Laura Panattoni1, Charles E Phelps2, Tracy A Lieu3, Stacey Alexeeff3, Suzanne O'Neill4,5, Jeanne S Mandelblatt4,5, Scott D Ramsey6. 1. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-B232, Seattle, WA, 98109, USA. 2. University of Rochester, Rochester, NY, USA. 3. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 4. Department of Oncology, Georgetown University Medical Center, Washington, DC, USA. 5. Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. 6. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-B232, Seattle, WA, 98109, USA. sramsey@fhcrc.org.
Abstract
OBJECTIVES: Chemotherapy is increasingly a preference-based choice among women diagnosed with early-stage breast cancer. Multicriteria decision analysis (MCDA) is a promising but underutilized method to facilitate shared decision making. We explored the feasibility of conducting an MCDA using direct rank ordering versus a time trade-off (TTO) to assess chemotherapy choice in a large population-based sample. METHODS: We surveyed 904 early-stage breast cancer survivors who were within 5 years of diagnosis and reported to the Western Washington State Cancer System and Kaiser Permanente Northern California registries. Direct rank ordering of 11 criteria and TTO surveys were conducted from September 2015 to July 2016; clinical data were obtained from registries or medical records. Multivariable regressions estimated post hoc associations between the MCDA, TTO, and self-reported chemotherapy receipt, considering covariates. RESULTS: Survivors ranged in age from 25 to 74 years and 73.9% had stage I tumors. The response rate for the rank ordering was 81.0%; TTO score was 94.2%. A one-standard deviation increase in the difference between the chemotherapy and no chemotherapy MCDA scores was associated with a 75.1% (95% confidence interval 43.9-109.7%; p < 0.001) increase in the adjusted odds of having received chemotherapy; no association was found between the TTO score and chemotherapy receipt. CONCLUSIONS: A rank-order-based MCDA was feasible and was associated with chemotherapy choice. Future research should consider developing and testing this MCDA for use in clinical encounters. Additional research is required to develop a TTO-based model and test its properties against a pragmatic MCDA to inform future shared decision-making tools.
OBJECTIVES: Chemotherapy is increasingly a preference-based choice among women diagnosed with early-stage breast cancer. Multicriteria decision analysis (MCDA) is a promising but underutilized method to facilitate shared decision making. We explored the feasibility of conducting an MCDA using direct rank ordering versus a time trade-off (TTO) to assess chemotherapy choice in a large population-based sample. METHODS: We surveyed 904 early-stage breast cancer survivors who were within 5 years of diagnosis and reported to the Western Washington State Cancer System and Kaiser Permanente Northern California registries. Direct rank ordering of 11 criteria and TTO surveys were conducted from September 2015 to July 2016; clinical data were obtained from registries or medical records. Multivariable regressions estimated post hoc associations between the MCDA, TTO, and self-reported chemotherapy receipt, considering covariates. RESULTS: Survivors ranged in age from 25 to 74 years and 73.9% had stage I tumors. The response rate for the rank ordering was 81.0%; TTO score was 94.2%. A one-standard deviation increase in the difference between the chemotherapy and no chemotherapy MCDA scores was associated with a 75.1% (95% confidence interval 43.9-109.7%; p < 0.001) increase in the adjusted odds of having received chemotherapy; no association was found between the TTO score and chemotherapy receipt. CONCLUSIONS: A rank-order-based MCDA was feasible and was associated with chemotherapy choice. Future research should consider developing and testing this MCDA for use in clinical encounters. Additional research is required to develop a TTO-based model and test its properties against a pragmatic MCDA to inform future shared decision-making tools.
Authors: Young Chandler; Clyde B Schechter; Jinani Jayasekera; Aimee Near; Suzanne C O'Neill; Claudine Isaacs; Charles E Phelps; G Thomas Ray; Tracy A Lieu; Scott Ramsey; Jeanne S Mandelblatt Journal: J Clin Oncol Date: 2018-01-08 Impact factor: 44.544
Authors: V M Duric; M R Stockler; S Heritier; F Boyle; J Beith; A Sullivan; N Wilcken; A S Coates; R J Simes Journal: Ann Oncol Date: 2005-08-26 Impact factor: 32.976
Authors: Jeanne S Mandelblatt; Vanessa B Sheppard; Arti Hurria; Gretchen Kimmick; Claudine Isaacs; Kathryn L Taylor; Alice B Kornblith; Anne-Michelle Noone; Gheorghe Luta; Michelle Tallarico; William T Barry; Lisa Hunegs; Robin Zon; Michael Naughton; Eric Winer; Clifford Hudis; Stephen B Edge; Harvey Jay Cohen; Hyman Muss Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Praveen Thokala; Nancy Devlin; Kevin Marsh; Rob Baltussen; Meindert Boysen; Zoltan Kalo; Thomas Longrenn; Filip Mussen; Stuart Peacock; John Watkins; Maarten Ijzerman Journal: Value Health Date: 2016-01-08 Impact factor: 5.725
Authors: G Thomas Ray; Jeanne Mandelblatt; Laurel A Habel; Scott Ramsey; Lawrence H Kushi; Yan Li; Tracy A Lieu Journal: Am J Manag Care Date: 2016-05-01 Impact factor: 2.229